---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-23-011292"
form_type: "8-K"
ticker: "IMDX"
cik: "0001642380"
company_name: "Insight Molecular Diagnostics Inc."
filed_at: "2023-04-06T23:59:59+00:00"
generated_at: "2026-06-17T05:11:06.683521+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oncocyte raises ~$13.5M in offering of 45.5M shares at $0.302-$0.354

## Summary
- Net proceeds of ~$13.5M after $250K advisory fee and other expenses.
- ~$1.1M used to redeem Series A Preferred stock; remainder for working capital and product commercialization.
- Broadwood Partners (largest shareholder) and board members participated as insiders at $0.35440 per share.
- Offering conducted as takedown from existing S-3 shelf registration statement declared effective June 2021.
- Company intends to use funds to support VitaGraft, DetermaIO, and DetermaCNI development.

## SEC filing metadata
- accession: 0001493152-23-011292
- form_type: 8-K
- ticker: IMDX
- cik: 0001642380
- company_name: Insight Molecular Diagnostics Inc.
- filed_at: 2023-04-06T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1642380/000149315223011292/0001493152-23-011292-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1642380/000149315223011292/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-23-011292
- JSON: https://secwatch.observer/filing/0001493152-23-011292.json
- Plain text: https://secwatch.observer/filing/0001493152-23-011292.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.